The major goal of this project is to develop an efficient and versatile gene delivery system using Rous sarcoma virus (RSV) for the genetic therapy of cystic fibrosis. The enzyme catalyzed viral integration makes retroviruses the most promising vector four long-term gene therapy. We have shown that RSV has a relaxed requirement for acquiring functional envelope proteins. Functional incorporation of influenza HA (or other respiratory trophic) envelope proteins into RSV makes it possible to create hybrid RSV inducing particles, bearing envelope proteins that will target airway cells. This will improve the efficiency an specificity of infection, enhance the safety of the gene delivery procedure and provide the capacity for repetitive gene transfer without provoking the host immune response. Our efforts will be focused on three areas; (a) Develop hybrid retroviruses that are targeted at human airway cells. We will optimize the infectivity of HA bearing RSV and test for additional envelope proteins that can mediate viral entry into airway epithelial cells. (b) Develop hybrid virus delivery systems. This will include construction of versatile RSV vectors to meet different requirements of CF gene therapy and establish high efficiency packaging cell lines for virion production. (c) Develop a practical in vivo gene transfer protocol. This will require optimizing the transduction efficiency of RSV hybrid viruses using marker gene expression and functional complementation studies in CF airway cells. This project will provide a novel approach to vector development for CF gene therapy that capitalizes on the unique properties of RSV as a delivery system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
7R01DK046177-03
Application #
2145360
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1992-09-30
Project End
1997-09-29
Budget Start
1994-09-30
Budget End
1995-09-29
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rubinchik, S; Ding, R; Qiu, A J et al. (2000) Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 7:875-85
Wang, D; Fischer, H; Zhang, L et al. (1999) Efficient CFTR expression from AAV vectors packaged with promoters--the second generation. Gene Ther 6:667-75
Zhang, L; Wang, D; Fischer, H et al. (1998) Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci U S A 95:10158-63
Fan, P D; Dong, J Y (1997) Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum Gene Ther 8:87-98
Dong, J Y; Fan, P D; Frizzell, R A (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7:2101-12
Dong, J Y; Wang, D; Van Ginkel, F W et al. (1996) Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 7:319-31